Home » Stocks » Applied Molecular Transport

Applied Molecular Transport, Inc. (AMTI)

Stock Price: $27.00 USD 1.28 (4.98%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 919.37M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 34.05M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $27.00
Previous Close $25.72
Change ($) 1.28
Change (%) 4.98%
Day's Open 26.44
Day's Range 25.56 - 27.48
Day's Volume 428,927
52-Week Range 17.05 - 31.84

More Stats

Market Cap 919.37M
Enterprise Value 903.16M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 34.05M
Float 4.37M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 354,589
Short Ratio 0.31
Short % of Float 2.22%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 45.51
Revenue n/a
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 16.20M
Net Cash / Share 0.48
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(28.41% upside)
Current: 27.00
Target: 34.67
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial Overview

No financial data available for this stock yet.

Company Profile

Company Details

Full Name Applied Molecular Transport, Inc.
Country United States
Employees 49
CEO Tahir Mahmood

Stock Information

Ticker Symbol AMTI
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: AMTI
IPO Date June 5, 2020


Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. Its lead product candidate is AMT-101, an oral gastrointestinal (GI) selective interleukin 10 that has completed a Phase 1b clinical trial in patients with ulcerative colitis (UC). The company, through its technology platform designs and develops various oral biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and RNA therapeutics. In addition, it engages in the development of AMT-126, a GI-selective oral fusion of rhIL-22 for diseases related to intestinal epithelium barrier function defects. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California.